普利製藥(300630.SZ)：與浙江大學簽訂《技術轉讓(專利申請權)合同》
格隆匯 8 月 31日丨普利製藥(300630.SZ)公佈，公司與浙江大學(以下簡稱“乙方”或“讓與方”)於2020年08月28日簽訂了《技術轉讓(專利申請權)合同》，本合同乙方擁有基於PLAT001項目的新藥開發及技術發明創造，甲方受讓該項技術發明的專利申請權和技術祕密並支付相應的轉讓價款。
合同的主要內容
受讓方(甲方):海南普利製藥股份有限公司
讓與方(乙方)：浙江大學
(一)合同標的：乙方擁有基於PLAT001項目的新藥開發及技術發明創造，甲方受讓該項技術發明的專利申請權和技術祕密並支付相應的轉讓價款；
(二)本合同轉讓的專利(申請)權和技術祕密：包括三項專利成果及一項技術祕密；
(三)交易價格：雙方同意本項目分期支付2000萬元技術轉讓費，及產品獲批上市後達成約定淨銷售額按相關比例進行的提成；
(四)支付方式：技術轉讓費按里程碑節點分期支付，銷售提成按照相應提成比例支付；
(五)轉讓條件：乙方同意甲方獨家開發PLAT001項目用於臨牀腫瘤治療藥物，實施地域範圍為全球範圍。
(六)違約責任：
1、甲方違反本合同發明創造專利申請權的價款及支付方式的約定，應當支付滯納金，滯納金以到期應付總額為基數，並按照1年期貸款年化利息的2倍(每天)計算，即違約金=應付金額*貸款基準利率(1年期)*2*滯納天數/360天計算(支付違約金或損失賠償額的計算方法)。
2、乙方違反本合同內向甲方提供技術資料和技術指導的約定，應當支付甲方已付款的10%為違約金。
3、乙方違反本合同向甲方提交技術資料的時間、地點、方式或保證本項技術祕密的實用性、可靠性以及實驗室規模水平的重現性的約定，應當支付甲方已付款的10%為違約金。
(七)合同生效：合同經合作各方簽字蓋章後生效。
本次合作本着優勢互補、互惠互利、平等合作的原則，藉助浙江大學強大的研發實力和平台優勢增強公司創新藥物研發實力,使公司在創新藥市場掌握先機，有利於公司聚焦主業，提升公司創新藥物研發實力，豐富公司研發產品線，增厚產品儲備，進一步提高公司核心競爭力，符合公司發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
